The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion

Background: Pre-clinical research with multi-potent adult progenitor cells (MAPC® cells, Multistem, Athersys Inc., Cleveland, Ohio) suggests their potential as an anti-inflammatory and immunomodulatory therapy in organ transplantation. Normothermic machine perfusion of the liver (NMP-L) has been pro...

Full description

Bibliographic Details
Main Authors: Richard W. Laing, Samantha Stubblefield, Lorraine Wallace, Valerie D. Roobrouck, Ricky H. Bhogal, Andrea Schlegel, Yuri L. Boteon, Gary M. Reynolds, Anthony E. Ting, Darius F. Mirza, Philip N. Newsome, Hynek Mergental, Simon C. Afford
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01226/full
id doaj-b3453b05dc9c4bec9a2bc4b80c5ab1ad
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Richard W. Laing
Richard W. Laing
Samantha Stubblefield
Lorraine Wallace
Valerie D. Roobrouck
Ricky H. Bhogal
Ricky H. Bhogal
Andrea Schlegel
Yuri L. Boteon
Yuri L. Boteon
Gary M. Reynolds
Anthony E. Ting
Darius F. Mirza
Darius F. Mirza
Philip N. Newsome
Philip N. Newsome
Hynek Mergental
Hynek Mergental
Simon C. Afford
Simon C. Afford
spellingShingle Richard W. Laing
Richard W. Laing
Samantha Stubblefield
Lorraine Wallace
Valerie D. Roobrouck
Ricky H. Bhogal
Ricky H. Bhogal
Andrea Schlegel
Yuri L. Boteon
Yuri L. Boteon
Gary M. Reynolds
Anthony E. Ting
Darius F. Mirza
Darius F. Mirza
Philip N. Newsome
Philip N. Newsome
Hynek Mergental
Hynek Mergental
Simon C. Afford
Simon C. Afford
The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion
Frontiers in Immunology
liver transplantation
organ preservation
organ donation
mesenchymal progenitor cells
machine perfusion
stem cell therapy
author_facet Richard W. Laing
Richard W. Laing
Samantha Stubblefield
Lorraine Wallace
Valerie D. Roobrouck
Ricky H. Bhogal
Ricky H. Bhogal
Andrea Schlegel
Yuri L. Boteon
Yuri L. Boteon
Gary M. Reynolds
Anthony E. Ting
Darius F. Mirza
Darius F. Mirza
Philip N. Newsome
Philip N. Newsome
Hynek Mergental
Hynek Mergental
Simon C. Afford
Simon C. Afford
author_sort Richard W. Laing
title The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion
title_short The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion
title_full The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion
title_fullStr The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion
title_full_unstemmed The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion
title_sort delivery of multipotent adult progenitor cells to extended criteria human donor livers using normothermic machine perfusion
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2020-06-01
description Background: Pre-clinical research with multi-potent adult progenitor cells (MAPC® cells, Multistem, Athersys Inc., Cleveland, Ohio) suggests their potential as an anti-inflammatory and immunomodulatory therapy in organ transplantation. Normothermic machine perfusion of the liver (NMP-L) has been proposed as a way of introducing therapeutic agents into the donor organ. Delivery of cellular therapy to human donor livers using this technique has not yet been described in the literature. The primary objectives of this study were to develop a technique for delivering cellular therapy to human donor livers using NMP-L and demonstrate engraftment.Methods: Six discarded human livers were perfused for 6 h at 37°C using the Liver Assist (Organ Assist, Groningen). 50 × 106 CMPTX-labeled MAPC cells were infused directly into the right lobe via the hepatic artery (HA, n = 3) or portal vein (PV, n = 3) over 20 min at different time points during the perfusion. Perfusion parameters were recorded and central and peripheral biopsies were taken at multiple time-points from both lobes and subjected to standard histological stains and confocal microscopy. Perfusate was analyzed using a 35-plex multiplex assay and proteomic analysis.Results: There was no detrimental effect on perfusion flow parameters on infusion of MAPC cells by either route. Three out of six livers met established criteria for organ viability. Confocal microscopy demonstrated engraftment of MAPC cells across vascular endothelium when perfused via the artery. 35-plex multiplex analysis of perfusate yielded 13 positive targets, 9 of which appeared to be related to the infusion of MAPC cells (including Interleukin's 1b, 4, 5, 6, 8, 10, MCP-1, GM-CSF, SDF-1a). Proteomic analysis revealed 295 unique proteins in the perfusate from time-points following the infusion of cellular therapy, many of which have strong links to MAPC cells and mesenchymal stem cells in the literature. Functional enrichment analysis demonstrated their immunomodulatory potential.Conclusion: We have demonstrated that cells can be delivered directly to the target organ, prior to host immune cell population exposure and without compromising the perfusion. Transendothelial migration occurs following arterial infusion. MAPC cells appear to secrete a host of soluble factors that would have anti-inflammatory and immunomodulatory benefits in a human model of liver transplantation.
topic liver transplantation
organ preservation
organ donation
mesenchymal progenitor cells
machine perfusion
stem cell therapy
url https://www.frontiersin.org/article/10.3389/fimmu.2020.01226/full
work_keys_str_mv AT richardwlaing thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT richardwlaing thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT samanthastubblefield thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT lorrainewallace thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT valeriedroobrouck thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT rickyhbhogal thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT rickyhbhogal thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT andreaschlegel thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT yurilboteon thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT yurilboteon thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT garymreynolds thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT anthonyeting thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT dariusfmirza thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT dariusfmirza thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT philipnnewsome thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT philipnnewsome thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT hynekmergental thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT hynekmergental thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT simoncafford thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT simoncafford thedeliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT richardwlaing deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT richardwlaing deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT samanthastubblefield deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT lorrainewallace deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT valeriedroobrouck deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT rickyhbhogal deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT rickyhbhogal deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT andreaschlegel deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT yurilboteon deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT yurilboteon deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT garymreynolds deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT anthonyeting deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT dariusfmirza deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT dariusfmirza deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT philipnnewsome deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT philipnnewsome deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT hynekmergental deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT hynekmergental deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT simoncafford deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
AT simoncafford deliveryofmultipotentadultprogenitorcellstoextendedcriteriahumandonorliversusingnormothermicmachineperfusion
_version_ 1724651153498570752
spelling doaj-b3453b05dc9c4bec9a2bc4b80c5ab1ad2020-11-25T03:12:10ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-06-011110.3389/fimmu.2020.01226537048The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine PerfusionRichard W. Laing0Richard W. Laing1Samantha Stubblefield2Lorraine Wallace3Valerie D. Roobrouck4Ricky H. Bhogal5Ricky H. Bhogal6Andrea Schlegel7Yuri L. Boteon8Yuri L. Boteon9Gary M. Reynolds10Anthony E. Ting11Darius F. Mirza12Darius F. Mirza13Philip N. Newsome14Philip N. Newsome15Hynek Mergental16Hynek Mergental17Simon C. Afford18Simon C. Afford19NIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomAthersys Inc., Cleveland, OH, United StatesNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomReGenesys BVBA, Leuven, BelgiumNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomAthersys Inc., Cleveland, OH, United StatesNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomNIHR Liver Biomedical Research Unit, Centre for Liver Research, College of Medical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United KingdomLiver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United KingdomBackground: Pre-clinical research with multi-potent adult progenitor cells (MAPC® cells, Multistem, Athersys Inc., Cleveland, Ohio) suggests their potential as an anti-inflammatory and immunomodulatory therapy in organ transplantation. Normothermic machine perfusion of the liver (NMP-L) has been proposed as a way of introducing therapeutic agents into the donor organ. Delivery of cellular therapy to human donor livers using this technique has not yet been described in the literature. The primary objectives of this study were to develop a technique for delivering cellular therapy to human donor livers using NMP-L and demonstrate engraftment.Methods: Six discarded human livers were perfused for 6 h at 37°C using the Liver Assist (Organ Assist, Groningen). 50 × 106 CMPTX-labeled MAPC cells were infused directly into the right lobe via the hepatic artery (HA, n = 3) or portal vein (PV, n = 3) over 20 min at different time points during the perfusion. Perfusion parameters were recorded and central and peripheral biopsies were taken at multiple time-points from both lobes and subjected to standard histological stains and confocal microscopy. Perfusate was analyzed using a 35-plex multiplex assay and proteomic analysis.Results: There was no detrimental effect on perfusion flow parameters on infusion of MAPC cells by either route. Three out of six livers met established criteria for organ viability. Confocal microscopy demonstrated engraftment of MAPC cells across vascular endothelium when perfused via the artery. 35-plex multiplex analysis of perfusate yielded 13 positive targets, 9 of which appeared to be related to the infusion of MAPC cells (including Interleukin's 1b, 4, 5, 6, 8, 10, MCP-1, GM-CSF, SDF-1a). Proteomic analysis revealed 295 unique proteins in the perfusate from time-points following the infusion of cellular therapy, many of which have strong links to MAPC cells and mesenchymal stem cells in the literature. Functional enrichment analysis demonstrated their immunomodulatory potential.Conclusion: We have demonstrated that cells can be delivered directly to the target organ, prior to host immune cell population exposure and without compromising the perfusion. Transendothelial migration occurs following arterial infusion. MAPC cells appear to secrete a host of soluble factors that would have anti-inflammatory and immunomodulatory benefits in a human model of liver transplantation.https://www.frontiersin.org/article/10.3389/fimmu.2020.01226/fullliver transplantationorgan preservationorgan donationmesenchymal progenitor cellsmachine perfusionstem cell therapy